Control group:osimertinib

2 trials

Sponsors

Affiliated Tumor Hospital of Guangxi Medical University, The Second Affiliated Hospital of He'nan University of Traditional Chinese Medicine

Conditions

Lung cancerlung cancer

Phase 3

A randomized, open-label, multicenter, phase III study of osimertinib plus chemotherapy versus osimertinib monotherapy in EGFR active mutant NSCLC with concomitant mutation

RecruitingChiCTR2100045604

Affiliated Tumor Hospital of Guangxi Medical UniversityLung cancer

Start: 2021-05-01Updated: 2021-12-06

Unknown Phase

Efficacy of Osimertinib combined with microwave ablation in (mut EGFR)NSCLC

RecruitingChiCTR2500111222

The Second Affiliated Hospital of He'nan University of Traditional Chinese Medicinelung cancer

Start: 2024-06-25Updated: 2025-11-03